MENU
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2024 All rights reserved. Tickeron Inc.

OKYO OKYO Pharma Limited Forecast, Technical & Fundamental Analysis

Industry Biotechnology
OKYO
Setup
Buy or SellView
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View Trends For OKYO
(Try 14 days for $1 only)
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
OKYO
Setup
Buy or SellView
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View Trends For OKYO
(Try 14 days for $1 only)
Ad is loading...
A.I. Advisor
published Earnings

OKYO is expected to report earnings to -9 cents per share on November 29

OKYO Pharma Limited OKYO Stock Earnings Reports
Q3'24
Est.
$-0.09
Q2'24
Est.
$-0.09
Q1'24
Est.
$-0.09
Q4'23
Est.
$-0.10
Q3'23
Est.
$-0.11
The last earnings report on August 28 showed earnings per share of -9 cents, meeting the estimate of -9 cents. With 29.64K shares outstanding, the current market capitalization sits at 35.02M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
14/15 Conduit St
Phone
+44 2074952379
Employees
3
Web
https://www.okyopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FIZZ46.270.62
+1.36%
National Beverage Corp
CBNK25.35-0.09
-0.35%
Capital Bancorp
MPWR860.66-6.65
-0.77%
Monolithic Power Systems
CNNE19.11-0.15
-0.78%
Cannae Holdings
DRRX1.35-0.07
-4.93%
DURECT Corp

OKYO and Stocks

Correlation & Price change

A.I.dvisor tells us that OKYO and MEIP have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OKYO and MEIP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OKYO
1D Price
Change %
OKYO100%
-2.42%
MEIP - OKYO
24%
Poorly correlated
+5.33%
CLNN - OKYO
24%
Poorly correlated
-5.10%
AKBA - OKYO
23%
Poorly correlated
-0.73%
URGN - OKYO
22%
Poorly correlated
+2.02%
IBIO - OKYO
21%
Poorly correlated
-4.28%
More